Replies to post #20028 on Oncolix Inc. (fka ONCX)

[JohnnyRothrock]

BioVectra video: subsidiary of NYSE Mallinckrodt-MNK 13g-filing shows they own 10,000,000 Common Shares of ONCX Oncolix Inc:

https://ih.advfn.com/stock-market/USOTC/oncolix-inc-ONCX/stock-news/79228265/statement-of-ownership-sc-13g


“BioVectra Inc. is a Mallinckrodt Pharmaceuticals company“

http://www.biovectra.com/about-us/


Mallinckrodt is a $1.77 billion dollar market cap biotech company thats been around 150 years:


http://www.mallinckrodt.com/about/150th-anniversary/

http://digitaleditions.walsworthprintgroup.com/publication/?i=435999#{"issue_id":435999,"page":0}


Mallinkckrodt symbol MNK chart:

http://www.thehotpennystocks.com/Stock-Quotes/?stock=MNK



-so with an OS less then 200 million for ONCX, i am simply following a billlion dollar biotech NYSE company’s lead and BioVectra and Mallinckrodt own due dilligence and teams of scientists, lawyers, Board, council and mgt who decided to buy 10 million shares of ONCX.

-meaning ONCX simply has proprietary biotech they dont have, and that has so much promise they are investing their own money in. Best of all for us they have bought Common Shares just like us. That’s fair, that’s square and that makes ONCX a very well-supported and serious penny biotech by any way you look at it.

Nothing runs like biotechs too so consistently over the decades and The Market watches biotechs very closely. And here we have ONCX at less then a penny and a low OS, first day of run and massive volume - anything could happen pps-wise this week.

[Omarprelude]

In regards to your post, trying to tie 1+1 together with Mallinckrodt and Oncolix. Perhaps it's the fact the Phase 1 clinical is scheduled to be completed in Feb 2019 as noted in the .gov website:

https://clinicaltrials.gov/ct2/show/study/NCT02534922


So, yeah - much, much more to the story??